Focus on new ideas and discoveries in antibody research and development -- 2018 new antibody drug Forum

Antibody drug is one of the fastest growing biological drugs, which has achieved great success in clinical and commercial fields However, there are also some problems that can not be ignored, such as complex and unstable structure, large-scale production and replication difficulties, long R & D cycle, high production costs The application of new technologies such as antibody engineering has brought the development of antibody drugs into a new development space At present, through the modification of antibody structure, people have developed some new directions of antibody drug research and development, such as antibody conjugates, bispecific antibodies, single domain antibodies (also known as nano antibodies) and other new antibodies A number of new antibody drugs have been registered or launched in Europe and the United States at the same time Biovalley will host the 2018 new antibody drug Forum on September 18, this meeting We will aim at the latest market trends, focus on the discovery and design of new antibody drugs, the selection of development strategies, and the transformation of new technologies and achievements We will invite top experts in the field of R & D and production of new antibody drugs at home and abroad to share the new market trends and technological breakthroughs, aiming to promote the development of domestic antibody drugs from following the development to independent R & D The meeting will build a platform for experts and industry leaders to exchange, share and cooperate, and jointly promote the healthy and rapid development of China's antibody drug industry Meeting time: September 18-19, 2018 meeting place: Shanghai Ocean Hotel (No 1171, dongdaming Road, Hongkou District) meeting form: speech + discussion + exhibition platform meeting official website: http://meeting.bioon.com/2018na meeting highlights: 1 Difficulties in discovery and design of new antibody drugs and solutions 2 Multi angle consideration on development strategy of new antibody drugs 3 Topics of the meeting: discovery and design of new antibody drugs - discovery and new mechanism of new antibody drugs - particularity of structure and function, design idea - selection and consideration of antibody sequence optimization - structural design of new antibody drugs combined with clinical needs - Design and technology of amino acid site modification- Process optimization design of antibody coupled Drugs Innovation Strategy of new antibody drug development advantages and clinical application prospect of new antibody drug development and innovation of new anti-tumor antibody drug development strategy selection of new antibody R & D strategy from the perspective of mass production demand key problems of new antibody drug properties overall quality control scheme of new antibody drug- New antibody drug R & D case sharing development mode and R & D strategy selection of R & D cooperation mode difficulties, risks and Strategies of commercial development product registration and application strategy preclinical safety evaluation scheme overall project design and development of clinical research patent protection strategy and scope proposed guests: he Miaozhuang Professor NIH of the United States Wu Chenbing, founder and CEO of Shanghai Anmai Biotechnology Co., Ltd., Ma Xingyuan, Professor of State Key Laboratory of Bioreactor Engineering, Feng Jiannan, researcher of Institute of basic medicine, Academy of Military Medical Sciences, Zhou Demin, Dean of School of pharmacy, Peking University, Fang Jianmin, general manager and chief scientific officer of Yantai Rongchang Biological Engineering Co., Ltd Qin Gang, founder and chairman of Qide Pharmaceutical Co., Ltd Zhou Pengfei, CEO of Wuhan youzhiyou biopharmaceutical Co., Ltd Liu Shigao, CEO of Fuhong Hanlin, Zhu Jianwei, Dean of School of pharmacy, Shanghai Jiaotong University, Xu Ting, CEO of Corning Jerry, Li Mengjie, Senior Quality Director of Sansheng Guojian / Shanghai antibody drug National Engineering Research Center, Qian Xueming, founder of mabos biology Zou Jianjun, chief medical officer of Hengrui medicine, Li Shengfeng, CEO of bio technology of baiaotai, Li Bohua, director of Shanghai protocell immunotherapy Research Office, Chen Chunlin, CEO of Shanghai medixi biology, Ren Jin, director of safety evaluation center of Shanghai Institute of medicine, Chinese Academy of Sciences, Luo Jianhui, drug evaluation center of State Food and drug administration, Zhao Xinyan, vice president of Xiansheng Pharmaceutical Biology Huang Gesheng, senior partner of Beijing zhongzi law firm, registration: From June 12 to June 22, Bio Valley grand launched the early bird ticket - 800 yuan / person (including the journal, lecture certificate and two-day tea break and lunch, excluding dinner and accommodation You can attend three parallel meetings: 2018 new antibody drug forum, 2018 (the third) protein modification and disease seminar, 2018 new vaccine Forum) Click "read the original" below to enter the official Sign up online Early bird ticket pre-sale will be closed on June 22, and the original price will be restored In the last few days, please hurry up to sign up Conference held at the same time contact: he Chunxing e-mail: chunxing.he@medsci.cn MT: 17321087523 wechat medsichiyi01 read the original